ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

IMAB I MAB

1,76
0,00 (0,00%)
23 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
I MAB IMAB NASDAQ Depository Receipt
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 1,76 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,77 1,7475 1,80 1,76 1,76
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
22.5.202413:00PRNUSI-Mab to Participate at the Jefferies Global Healthcare..
30.4.202413:00PRNUSI-MAB Filed 2023 Annual Report on Form 20-F
05.4.202413:00PRNUSI-Mab to Participate at the 23rd Annual Needham Virtual..
02.4.202422:01PRNUSI-Mab Announces Closing of the Divestiture of Business..
14.3.202422:00PRNUSI-Mab Reports Full Year 2023 Financial Results and Business..
09.2.202422:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08.2.202412:07EDGAR2Form 144 - Report of proposed sale of securities
07.2.202412:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07.2.202412:00PRNUSI-Mab Signs Agreement to Divest its Assets and Business..
07.2.202402:55EDGAR2Form SCHEDULE 13G - Statement of acquisition of beneficial..
06.2.202412:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.1.202412:21EDGAR2Form 144 - Report of proposed sale of securities
02.1.202423:08DJNADRs Slump; FLJ Group Declines 21%
29.12.202312:12EDGAR2Form 144 - Report of proposed sale of securities
26.12.202312:22EDGAR2Form 144 - Report of proposed sale of securities
01.12.202320:41EDGAR2Form SC 13D - General statement of acquisition of beneficial..
16.11.202312:43EDGAR2Form 144 - Report of proposed sale of securities
06.11.202314:00PRNUSI-Mab Announces Participation at Jefferies and Piper..
02.11.202313:00PRNUSFelzartamab Granted Breakthrough Therapy Designation by U.S...
01.11.202313:00PRNUSI-Mab Announces Poster Presentations of 4-1BB Bispecific..
16.10.202314:00PRNUSI-Mab Announces Phase 1 Data of Givastomig at ESMO 2023
10.10.202317:04EDGAR2Form 144 - Report of proposed sale of securities
10.10.202314:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10.10.202314:00PRNUSI-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB..
29.9.202312:15EDGAR2Form 144 - Report of proposed sale of securities
22.9.202322:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05.9.202314:00PRNUSI-Mab Announces Upcoming Participation at September..
17.8.202312:52EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17.8.202312:00PRNUSI-Mab Provides Mid-Year 2023 Financial Results, Business and..
08.8.202314:00PRNUSI-Mab to Report Mid-Year 2023 Financial Results, Business..
11.7.202312:17EDGAR2Form 144 - Report of proposed sale of securities
05.7.202314:39EDGAR2Form 144 - Report of proposed sale of securities
05.7.202314:34EDGAR2Form 144 - Report of proposed sale of securities
05.7.202314:22EDGAR2Form 144 - Report of proposed sale of securities
05.7.202314:00PRNUSI-Mab Announces Publication of Claudin18.2 x 4-1BB..
22.6.202314:00PRNUSI-Mab Announces the Appointment of Raj Kannan as CEO
25.5.202323:01PRNUSI-Mab Announces Encouraging Phase 1b/2 Study Results of..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock